Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

Festi D, Schiumerini R, Scaioli E, Colecchia A

MeSH — NLM indexing Fatty Liver / diagnosis Humans

Staff actions

Files are for authorised use within BioPredictive partner channels only.

Fibrotest Actitest Letter Independent Group Italy

Authors (4)

Citation

Festi D, Schiumerini R, Scaioli E, Colecchia A. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply. Aliment Pharmacol Ther. 2013;37(6):656-7. doi:10.1111/apt.12228.

Identifiers

DOI: 10.1111/apt.12228
PMID: 23406410

Tests

Liver diseases

Liver injuries

Subjects

Region

Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

More by Festi D

Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

More on the same topic

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Toward non-invasive assessment strategies in autoimmune hepatitis.

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.